Completed PHASE3 INTERVENTIONAL NCT00807690

Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus Placebo

Treatment of Vitiligo With Narrowband UVB (TL01) Combined With Tacrolimus (0.1%) Versus Placebo Ointment, a Randomized Right/Left Double Blind Comparative Study

Sponsor: Oslo University Hospital

Conditions Vitiligo

Interventions Tacrolimus ointment

Updated 4 times since 2017 Last updated: Dec 11, 2008 Started: Nov 30, 2005 Completion: Jan 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Vitiligo and is currently completed. Oslo University Hospital leads this study, which shows 4 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2017 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oslo University Hospital

Data source: Oslo University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.